Conjugado processo para tratamento de uma doença em um mamífero e composição farmacêutica

A novel conjugate comprises a target seeking moiety and a modified wild type superantigen; the modified superantigen retains its ability to activate a subset of T cells, even though 1 or more wild-type amino acid residues in at least 1 region which functions in determining binding to T cell receptor...

Full description

Saved in:
Bibliographic Details
Main Authors LARS ABRAHMSEN, TERJE KALLAND, PER BJOERK, PER ANTONSSON, JOHAN HANSSON, MIKAEL DOHLSTEN, GOERAN FORSBERG
Format Patent
LanguagePortuguese
Published 16.03.1999
Edition6
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A novel conjugate comprises a target seeking moiety and a modified wild type superantigen; the modified superantigen retains its ability to activate a subset of T cells, even though 1 or more wild-type amino acid residues in at least 1 region which functions in determining binding to T cell receptor (TCR)and activation of a subset of T cells has/have been replaced. Also claimed is the use of a modified superantigen as above, optionally as part of a conjugate with a target seeking moiety, for activating the immune system to treat a mammalian disease. Also new is a pharmaceutical composition comprising a modified antibody (preferably a Fab fragment fused to a peptide moiety providing activation of T cells in V~b specific manner) in which cysteines providing for interchain cysteine linkages in the native antibody have been replaced (preferably by serine residues) to prohibit cystine formation.
Bibliography:Application Number: BR19979702179